Story perspectives

FDA Reviews RSV Drugs Amid Vaccine Guidance Controversy

12/10/2025

Summary

Story summary

The U.S. Food and Drug Administration has opened a safety review of two injectable RSV drugs from Merck and Sanofi.
The review coincides with Health Secretary Robert F. Kennedy Jr.'s rollback of routine childhood vaccinations.
Merck and Sanofi report no new safety concerns about their RSV products.
Kennedy's leadership has driven vaccine guidance changes, including a panel's call to end routine hepatitis B vaccinations for newborns, triggering backlash.

1 of 1

Story summary

The U.S. Food and Drug Administration has opened a safety review of two injectable RSV drugs from Merck and Sanofi.
The review coincides with Health Secretary Robert F. Kennedy Jr.'s rollback of routine childhood vaccinations.
Merck and Sanofi report no new safety concerns about their RSV products.
Kennedy's leadership has driven vaccine guidance changes, including a panel's call to end routine hepatitis B vaccinations for newborns, triggering backlash.